Molecular subtypes of breast cancers detected in mammography screening and outside of screening

Clinical Cancer Research

Volumn 14, Issue 13, 2008, Pages 4103-4110

  Sihto, Harri ^a   Lundin, Johan ^a,b   Lehtimäki, Tiina ^a   Sarlomo Rikala, Maarit ^a   Bützow, Ralf ^a   Holli, Kaija ^c   Sailas, Liisa ^d   Kataja, Vesa ^d,e   Lundin, Mikael ^a   Turpeenniemi Hujanen, Taina ^f   Isola, Jorma ^c   Heikkilä, Päivi ^a   Joensuu, Heikki ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FOLKHÄLSAN RESEARCH CENTER   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d VAASA CENTRAL HOSPITAL   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER SCREENING; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAMMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; FINLAND; GENETICS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REGISTER; TIME;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FINLAND; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; RECEPTOR, ERBB-2; REGISTRIES; TIME FACTORS;

EID: 48249101964     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5003     Document Type: Article

References (38)

1. Senie RT, Lesser M, Kinne DW, Rosen PP. Method of tumor detection influences disease-free survival of women with breast carcinoma. Cancer 1994;73: 1666-72.
2. Burrell HC, Sibbering DM, Wilson AR, et al. Screening interval breast cancers: mammographic features and prognostic factors. Radiology 1996;199:811-7.
3. Moody-Ayers SY, Wells CK, Feinstein AR. "Benign" tumors and "early detection" in mammographyscreened patients of natural cohort with breast cancer. Arch Intern Med 2000;160:1109-15.
4. Porter PL, El-Bastawissi AY, Mandelson MT, et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 1999;91: 2020-8.
5. Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR. Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res 1999;5:2682-8.
6. Groenendijk RP, Bult P, Tewarie L, et al. Screendetected breast cancers have a lower mitotic activity index. Br J Cancer 2000;82:381-4.
7. Joensuu H, Lehtimäki T, Holli K, et al. Risk for distant recurrence of breast cancer detected by mammography screening or other means. JAMA 2004;292: 1064-73.
8. ShenY, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005;97:1195-203.
9. Kopans DB, Monsees B, Feig SA. Screening for cancer: when is it valid? Lessons from the mammography experience. Radiology 2003;229:319-27.
10. Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004;328:921-4.
11. SørlieT, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
12. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
13. Kang YB, Siegel PM, Shu WP, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49
14. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-nodenegative primary breast cancer. Lancet 2005;365: 671-9.
15. Naume B, Zhao X, Synnestvedt M, et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol 2007;1:160-71.
16. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100:8418-23.
17. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
18. Hoch RV, Thompson DA, Baker RJ, Weigel RJ. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer 1999;84:122-8.
19. Laakso M, Tanner M, Nilsson J, et al. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 2006;12:4185-91.
20. Lundin J, Lundin M, Holli K, et al. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol 2001; 19:28-36.
21. 0 breast cancer: a nationwide populationbased study. Clin Cancer Res 2003;9:923-30.
22. Ristimäki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
23. Lassus H, Sihto H, Leminen A, et al. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med 2006;84:671-81.
24. Sihto H, Tynninen O, Bützow R, Saarialho-Kere U, Joensuu H. Endothelial cell KIT expression in human tumors. J Pathol 2007;211:481-8.
25. Brekelmans CT, Westers P. Faber JA, Peeters PH, Collette HJ. Age specific sensitivity and sojourn time in a breast cancer screening programme (DOM) inThe Netherlands: a comparison of different methods. J Epidemiol Community Health 1996;50:68-71.
26. Paci E, Duffy SW. Modelling the analysis of breast cancer screening programmes: sensitivity, lead time and predictive values in the Florence district programme (1975-1986). IntJ Epidemiol 1991;20:852-8.
27. Boer R, de Koning H, Threlfall A, et al. Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study. BMJ 1998;317:376-9.
28. Boer R, de Koning HJ, van der Maas PJ. A longer breast carcinoma screening interval for women age older than 65 years? Cancer1999;86:1506-10.
29. Collett K, Stefansson IM, Eide J, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005:14:1108-12.
30. Diallo-Danebrock R, Ting E, Gluz O, et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res 2007;13:488-97
31. Hannemann J, Kristel P, vanTinteren H, et al. Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 2006;95:1334-41.
32. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
33. Conforti R, BouletT, Tomasic G, et al. Breast cancer molecular subclassification and estrogen receptor expression to efficacy of adjuvant anthracycline-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol 2007;18:1477-83.
34. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/ neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651-64
35. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer Cancer Res 1990;50:4332-7
36. Asselin-Labat ML, Sutherland KD, Barker H, et al Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation Nat Cell Biol 2007;9:201-9.
37. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006;208:495-506.
38. Naylor MJ, Ormandy CJ. Gata-3 and mammary cell fate. Breast Cancer Res 2007;9:302